A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population

This study has been completed.
Sponsor:
Information provided by:
Braintree Laboratories
ClinicalTrials.gov Identifier:
NCT00425594
First received: January 19, 2007
Last updated: December 20, 2007
Last verified: December 2007

January 19, 2007
December 20, 2007
January 2007
May 2007   (final data collection date for primary outcome measure)
Efficacy - preparation quality using a 4-point scale
Same as current
Complete list of historical versions of study NCT00425594 on ClinicalTrials.gov Archive Site
Safety - patient reported preparation related side effects. Pre and post preparation analysis of serum chemistry.
Same as current
Not Provided
Not Provided
 
A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population
A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population

This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Colonoscopy
  • Drug: HalfLytely and Bisacodyl Tablets - Formulation 1
  • Drug: HalfLytely and Bisacodyl Tablets - Formulation 2
  • Drug: NuLYTELY
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
May 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients who are undergoing colonoscopy for a routinely accepted indication, including:

    • Evaluation of BE results
    • Endosonography
    • Blood in stool
    • Anemia of unknown etiology
    • Abdominal Pain
    • Polypectomy
    • Unknown diarrhea or constipation etiology
    • Inflammatory bowel disease
  • Between 6 and 16 years of age at screening.
  • Otherwise in good health, as determined by physical exam and medical history.
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse).
  • Negative urine pregnancy test at screening, if applicable
  • In the investigator's judgment, parent/guardian is mentally competent to provide informed consent to participate in the study.

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon
  • Subjects impacted at screening
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal and decompression
  • Subjects with known difficulties for swallowing tablets
  • Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics.
  • Subjects who are taking drugs that may affect electrolyte levels with the exception of routine diuretics.
  • Subjects with known clinically significant electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
  • Any condition in parent/guardian associated with poor subject compliance (e.g., substance abuse); inability of parent/guardian to return for scheduled visits with their child.
Both
6 Years to 16 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00425594
F38-25
No
John McGowan, Clinical Operations Manager, Braintree Laboratories, Inc.
Braintree Laboratories
Not Provided
Study Director: John McGowan Braintree Laboratories, Inc.
Braintree Laboratories
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP